Arya Mehrabanzad
Direktor/Vorstandsmitglied bei Genome Diagnostics BV
Profil
Mr. Arya Mehrabanzad is a Vice President at Ampersand Management LLC.
He is on the Board of Directors at Genome Diagnostics BV.
He received his undergraduate degree from Harvard University.
Aktive Positionen von Arya Mehrabanzad
| Unternehmen | Position | Beginn |
|---|---|---|
Ampersand Management LLC
 Ampersand Management LLC Investment ManagersFinance Ampersand Management LLC (Ampersand Management) is a private equity firm founded in 1988 by Richard A. Charpie. The firm is headquartered in Wellesley, Massachusetts. | Private-Equity-Analyst | 01.09.2016 |
Genome Diagnostics BV
 Genome Diagnostics BV Medical SpecialtiesHealth Technology Genome Diagnostics BV develops and markets vitro diagnostic tests and services, analysis software & education. Its products include NGSengine, SBTexcellerator, AlleleSEQR and SBTengine. The company was founded by Martijn Rozemuller, Wietse Mulder, Oscar Schoots, and Raoul Linschoten in March 2005 and is headquartered in Utrecht, the Netherlands. | Direktor/Vorstandsmitglied | - |
Ausbildung von Arya Mehrabanzad
| Harvard University | Undergraduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Private Unternehmen | 2 |
|---|---|
Ampersand Management LLC
Ampersand Management LLC Investment ManagersFinance Ampersand Management LLC (Ampersand Management) is a private equity firm founded in 1988 by Richard A. Charpie. The firm is headquartered in Wellesley, Massachusetts. | Finance |
Genome Diagnostics BV
Genome Diagnostics BV Medical SpecialtiesHealth Technology Genome Diagnostics BV develops and markets vitro diagnostic tests and services, analysis software & education. Its products include NGSengine, SBTexcellerator, AlleleSEQR and SBTengine. The company was founded by Martijn Rozemuller, Wietse Mulder, Oscar Schoots, and Raoul Linschoten in March 2005 and is headquartered in Utrecht, the Netherlands. | Health Technology |
